Compare Natera Inc. Common Stock (NTRA) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $27.63 (market cap $2.08B). The key difference: Natera Inc. Common Stock is far larger — about 27.4× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 30 Days on average.
| NTRA | TMF | |
|---|---|---|
Market Cap | $57.03B | $2.08B |
Volume | 1,131,157 | 5,652,065 |
Sector | Health | Fixed Income |
52-Week High | $425.64 | $44.14 |
52-Week Low | $179.42 | $25.19 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TMF, a leveraged ETF tracking long-term Treasury bonds, trades at $26.38, up 1.15% with elevated volume. Technical indicators are bearish overall, with moving averages and oscillators signaling caution. The stock lacks traditional fundamental metrics like P/E or revenue, as it is an ETF, and its value is tied to interest rate expectations. Recent news highlights strong trading volume, suggesting heightened investor attention amid bond market volatility.
The outlook for TMF hinges on interest rate trends, with potential upside if rates fall but significant downside risk if they rise. Investors face volatility from macroeconomic shifts and the ETF's leveraged structure, which amplifies gains and losses. Key risks include Federal Reserve policy changes and inflation dynamics, making it suitable only for those comfortable with high risk and short-term trading.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
